The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Trastuzumab Biosimilars Market Between 2026 And 2030?
The size of the trastuzumab biosimilars market has experienced substantial expansion in recent years. It is anticipated to increase from $6.9 billion in 2025 to $8.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.5%. This growth observed in the past can be attributed to factors such as the high incidence of HER2 positive breast cancer, the expiration of trastuzumab’s patent, rising oncology drug costs, the establishment of regulatory biosimilar pathways, and greater adoption within hospital oncology settings.
The trastuzumab biosimilars market is anticipated to experience substantial expansion over the coming years, with its size projected to reach $24.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. This projected growth during the forecast period is primarily driven by factors such as the rising incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, increasing trust among physicians, and initiatives aimed at controlling healthcare costs. Key trends expected during the same period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted treatments, competitive pricing strategies in breast cancer therapy, an increase in oncology usage within hospitals, and a growing willingness to switch to biosimilar alternatives.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp
What Market Drivers Are Helping Shape The Trastuzumab Biosimilars Market Expansion?
The increased incidence of breast and gastric cancer has significantly contributed to the expansion of the trastuzumab biosimilars market. Trastuzumab biosimilars are utilized in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For example, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, projected around 297,790 new cases of invasive breast cancer to be diagnosed in women in 2023, with approximately 43,700 women expected to succumb to breast cancer in the same year. Moreover, Cancer India states that breast cancer is the most common cancer among women in India, constituting 14% of all cancers in women. This escalating prevalence of breast and gastric cancer consequently drives the demand for trastuzumab biosimilars, which provide a more economical alternative to expensive medicines, thereby propelling the trastuzumab biosimilars market.
What Are The Core Segment Classifications In The Trastuzumab Biosimilars Market?
The trastuzumab biosimilars market covered in this report is segmented –
1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy
Which Trends Are Contributing To Changes In The Trastuzumab Biosimilars Market?
Leading industry participants are consistently prioritizing the introduction of novel products into previously unaddressed territories, which is significantly influencing the market for trastuzumab biosimilars. Organizations active within the trastuzumab biosimilars market are implementing diverse strategic initiatives, including the creation of new products, fostering collaborations, and expanding their geographical reach and product portfolios, all aimed at sustaining their competitive edge and more effectively addressing customer demands. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA) had granted approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), intended for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While HER2-positive cancers are typically aggressive, they demonstrate effective responses to targeted therapies. HERCESSI operates by binding to the HER2 receptor, thereby inhibiting its activity and consequently slowing down the replication of cancer cells.
Which Companies Form The Competitive Landscape Of The Trastuzumab Biosimilars Market?
Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited
Access The Complete Trastuzumab Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report
Which Region Has The Strongest Presence In The Trastuzumab Biosimilars Market?
North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Trastuzumab Biosimilars Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp
Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Oncology Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Oral Biologics And Biosimilars Market 2026
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model